Developmental Funds are at the core of CSHL Cancer Center's ambitious research program. They offer the Cancer Center Executive Committee the opportunity to strategically promote exciting new projects, expand research initiatives with energetic new faculty, and develop or acquire the latest technologies in Shared Resources. Developmental Funds are used at the discretion of the Cancer Center Director and other senior Cancer Center members to recruit and support new faculty hires, which is a highly sucessful application of these resources. These investigators have gone on to establish vibrant and productive cancer-research programs and succesfully obtain independent peer reviewed funding. The Developmental Funds also support novel pilot projects, often with clinically applicable results. Indeed, one such project has already brought a drug into early stage clinical trials. The Cancer Center Leaders also direct Developmental Funds to investigators who are pioneering new technology and experimental approaches. As a whole, Developmental Funds are an extremely valuable source of support that is enabling the CSHL Cancer Center to understand the biological mechanisms underlying cancer while developing new therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA045508-33
Application #
9975709
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
33
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Cold Spring Harbor Laboratory
Department
Type
DUNS #
065968786
City
Cold Spring Harbor
State
NY
Country
United States
Zip Code
11724
Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129
Forcier, Talitha L; Ayaz, Andalus; Gill, Manraj S et al. (2018) Measuring cis-regulatory energetics in living cells using allelic manifolds. Elife 7:
Naguib, Adam; Mathew, Grinu; Reczek, Colleen R et al. (2018) Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep 23:58-67
Aberle, M R; Burkhart, R A; Tiriac, H et al. (2018) Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg 105:e48-e60
Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804
Khan, Jalal A; Maki, Robert G; Ravi, Vinod (2018) Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. J Clin Oncol 36:194-201
Chen, Wei-Chia; Tareen, Ammar; Kinney, Justin B (2018) Density Estimation on Small Data Sets. Phys Rev Lett 121:160605
Cheng, Derek; Tuveson, David (2018) Kras in Organoids. Cold Spring Harb Perspect Med 8:
Albrengues, Jean; Shields, Mario A; Ng, David et al. (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361:
Cook, Natalie; Basu, Bristi; Smith, Donna-Michelle et al. (2018) A phase I trial of the ?-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 118:793-801

Showing the most recent 10 out of 380 publications